Last €6.16 EUR
Change Today +0.241 / 4.08%
Volume 0.0
N8R On Other Exchanges
As of 10:10 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

imperial innovations group p (N8R) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/2/15 - €6.39
52 Week Low
05/21/14 - €4.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

imperial innovations group p (N8R) Related Businessweek News

No Related Businessweek News Found

imperial innovations group p (N8R) Details

Imperial Innovations Group plc is a venture capital and private equity firm specializing in all stages of development including incubation, seed, early stage, growth capital, development funding, and later stage investments. The firm typically invests in all sectors. It focuses on technology, all-things-saas (software-as-a-service), analytics, security, bioengineering, therapeutics, software, hardware, healthcare, medical devices, and diagnostics, energy, engineering, materials, clean tech, digital, environment, and bioscience companies founded by or based on technology and intellectual property from the University of Oxford, the University of Cambridge, Imperial College, and University College, London. It primarily invests in companies based in the United Kingdom. The firm typically invests between £0.02 million ($0.03 million) and £1 million ($1.71 million). It also invests between £1 million ($1.71 million) and £5 million ($8.55 million) and further between £5 million ($8.55 million) and above £25 million ($42.76 million) for stake building purposes. The firm prefers to lead or co-lead its investments. It also makes subsequent funding technology rounds working in partnership with founders, management, and co-investors. The firm seeks to take a board seat on its portfolio companies. It also provides technology transfer services and targets companies based on the intellectual property from Imperial College. Imperial Innovations Group plc was founded in 1986 and is based in London, the United Kingdom with an additional office in Cambridge, United Kingdom.

64 Employees
Last Reported Date: 11/12/14
Founded in 1986

imperial innovations group p (N8R) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 403.0K GBP
Managing Director of Technology Transfer Offi...
Total Annual Compensation: 135.0K GBP
Chief Investment Officer, Director and Member...
Total Annual Compensation: 352.0K GBP
Compensation as of Fiscal Year 2014.

imperial innovations group p (N8R) Key Developments

Imperial Innovations Group plc Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Imperial Innovations Group plc Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Cell Therapy Catapult, UCL Business and Imperial Innovations Announces First Patient in Trial Given New T-Cell Therapy for Leukaemia

A patient with acute myeloid leukaemia has been given the first experimental T-cell therapy in a Phase I/ll trial1 being undertaken by Catapult Therapy TCR Ltd, a partnership established in July 2014 to accelerate development of this experimental treatment. The trial is expected to involve five centres in the UK and will assess the safety and efficacy of the T cell receptor (TCR) therapy, which targets diseases associated with over expression of the WT1 antigen. Catapult Therapy TCR is a partnership between the Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation's health and wealth, UCL Business (UCLB) and Imperial Innovations. The new therapy was developed initially at Imperial College London and then at UCL by scientists funded by the charity Leukaemia & Lymphoma Research. Using TCR gene-modified T cells to target WT1-over expressing cells, it shows potential in disorders such as acute myeloid leukaemia and myelodysplastic syndrome. The treatment involves modification by gene therapy of the patient's own T cells, so that they may recognise and destroy WT1-expressing cells when infused back into the body. Following promising initial preclinical work on the therapy, Catapult Therapy TCR Limited was established to progress it through Phase II clinical trials and manufacturing process development. A second trial involving the therapy, in myelodysplastic syndrome, is expected to start in 2015.

Imperial Innovations Group plc, Annual General Meeting, Dec 16, 2014

Imperial Innovations Group plc, Annual General Meeting, Dec 16, 2014., at 10:30 GMT Standard Time. Location: The Boardroom, 52 Princes Gate. Agenda: To receive and adopt the Directors' report and the audited accounts for the year ended 31 July 2014 and to note that the Directors do not recommend the payment of any dividend for the year ended on that date; to elect Peter Chambré as a Director of the company; to elect Dr. Linda Wilding as a Director of the company; to re-elect Dr. Martin Knight as a Director of the company; to re-elect Mark Rowan as a Director of the company; to re-appoint PricewaterhouseCoopers LLP as auditors, to hold office from the conclusion of the AGM until the conclusion of the next AGM; to authorise the Directors to determine the auditors' remuneration; to receive and approve the Directors' remuneration report for the year ended 31 July 2014; and to consider special business.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
N8R:GR €6.16 EUR +0.241

N8R Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Health Discovery Corp $0.02 USD 0.00
MDxHealth €5.10 EUR +0.139
Miraculins Inc C$0.18 CAD +0.01
Myriad Genetics Inc $34.34 USD +0.04
Vermillion Inc $1.83 USD +0.0401
View Industry Companies

Industry Analysis


Industry Average

Valuation N8R Industry Range
Price/Earnings 15.3x
Price/Sales 119.3x
Price/Book 1.4x
Price/Cash Flow 20.5x
TEV/Sales 153.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPERIAL INNOVATIONS GROUP P, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at